These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10356737)

  • 41. The many facets of melioidosis.
    Dharakul T; Songsivilai S
    Trends Microbiol; 1999 Apr; 7(4):138-40. PubMed ID: 10217823
    [No Abstract]   [Full Text] [Related]  

  • 42. Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis.
    Casey WT; Spink N; Cia F; Collins C; Romano M; Berisio R; Bancroft GJ; McClean S
    Vaccine; 2016 May; 34(23):2616-21. PubMed ID: 27091689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Experimental substantiation of the possibility of aerosol immunization with a live tularemia vaccine].
    Agafonov VI; Gapochko KG; Libikh I; Misnikov OP; Erikhleb M
    Zh Mikrobiol Epidemiol Immunobiol; 1978 Sep; (9):33-6. PubMed ID: 747027
    [No Abstract]   [Full Text] [Related]  

  • 44. Progress toward development of vaccines against melioidosis: A review.
    Sarkar-Tyson M; Titball RW
    Clin Ther; 2010 Aug; 32(8):1437-45. PubMed ID: 20728758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate.
    Scott AE; Ngugi SA; Laws TR; Corser D; Lonsdale CL; D'Elia RV; Titball RW; Williamson ED; Atkins TP; Prior JL
    J Immunol Res; 2014; 2014():392170. PubMed ID: 24892035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis.
    Nelson M; Prior JL; Lever MS; Jones HE; Atkins TP; Titball RW
    J Med Microbiol; 2004 Dec; 53(Pt 12):1177-1182. PubMed ID: 15585494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.
    Muruato LA; Tapia D; Hatcher CL; Kalita M; Brett PJ; Gregory AE; Samuel JE; Titball RW; Torres AG
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28903988
    [No Abstract]   [Full Text] [Related]  

  • 48. [The protective properties of the outer membranes of Francisella tularensis in an experimental infection in guinea pigs].
    Khlebnikov VS; Golovlev IR; Chugunov AM; Zhemchugov VE; Averin SF; Afanas'ev SS; Pshirkov SIu; Konovalov SI; Stepanov AV
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (1):84-8. PubMed ID: 8184621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.
    Bondi SK; Goldberg JB
    Expert Rev Vaccines; 2008 Nov; 7(9):1357-65. PubMed ID: 18980539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A model of immunity to Burkholderia pseudomallei: unique responses following immunization and acute lethal infection.
    Ulett GC; Labrooy JT; Currie BJ; Barnes JL; Ketheesan N
    Microbes Infect; 2005; 7(11-12):1263-75. PubMed ID: 16027024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.
    Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA
    Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of CD4+ T-cell epitope and investigation of HLA distribution for the immunogenic proteins of Burkholderia pseudomallei using in silico approaches - A key vaccine development strategy for melioidosis.
    Swetha RG; Sandhya M; Ramaiah S; Anbarasu A
    J Theor Biol; 2016 Jul; 400():11-8. PubMed ID: 27086038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exopolysaccharides of Burkholderia pseudomallei.
    Steinmetz I; Nimtz M; Wray V; Häussler S; Reganzerowski A; Brenneke B
    Acta Trop; 2000 Feb; 74(2-3):211-4. PubMed ID: 10674651
    [No Abstract]   [Full Text] [Related]  

  • 54. [Immunogenic potential of glanders and melioidosis agents].
    Kalachev II; Baídus' AN; Ivanova OA; Ganina EA; Boldyrev IA; Svetoch EA
    Vestn Ross Akad Med Nauk; 1997; (6):32-7. PubMed ID: 9289277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Tularemia vaccine strain is a potential vector].
    Pavlov VM; Mokrievich AN; Noskov AN; Urakov NN
    Vestn Ross Akad Med Nauk; 1997; (6):30-2. PubMed ID: 9289276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Burkholderia thailandensis: biological properties, identification and taxonomy].
    Iliukhin VI; Senina TV; Plekhanova NG; Antonov VA; Merinova LK; Seimova IK
    Mol Gen Mikrobiol Virusol; 2002; (1):7-11. PubMed ID: 11904924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent development in melioidosis.
    Leelarasamee A
    Curr Opin Infect Dis; 2004 Apr; 17(2):131-6. PubMed ID: 15021053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polysaccharides and virulence of Burkholderia pseudomallei.
    Sarkar-Tyson M; Thwaite JE; Harding SV; Smither SJ; Oyston PCF; Atkins TP; Titball RW
    J Med Microbiol; 2007 Aug; 56(Pt 8):1005-1010. PubMed ID: 17644705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets.
    Hara Y; Mohamed R; Nathan S
    PLoS One; 2009 Aug; 4(8):e6496. PubMed ID: 19654871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virulence of the Melioidosis Pathogen Burkholderia pseudomallei Requires the Oxidoreductase Membrane Protein DsbB.
    McMahon RM; Ireland PM; Sarovich DS; Petit G; Jenkins CH; Sarkar-Tyson M; Currie BJ; Martin JL
    Infect Immun; 2018 May; 86(5):. PubMed ID: 29440370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.